

## Special Issue

# Imaging-Guided Interventional Cancer Combination Immunotherapy

### Message from the Guest Editor

The development of novel treatment approaches will further advance our knowledge and support our fight to cure cancer. With state-of-the-art equipment for cancer research, our research group has focused on novel image-guided cancer immunotherapy including immune checkpoint inhibitors, natural killer and dendritic cell-based immunotherapy, image-guided small molecular inhibitor and antibody immunotherapy, image-guided combination therapies of local ablation and targeted immunotherapy, image-guided drug delivery for cancer and utilization of artificial intelligence for the prediction of prognosis and evaluation of clinical outcomes. Our research team investigates rabbit, mouse and rat tumor models to optimize and develop MRI sequences for the assessment of therapeutic responses.

---

### Guest Editor

Prof. Dr. Zhuoli Zhang

Radiology, University of California, Irvine, CA 92617, USA

---

### Deadline for manuscript submissions

closed (31 May 2025)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/si/210928](https://mdpi.com/si/210928)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)